Is N-acetylcysteine infusion an effective treatment option in L-asparaginase associated hepatotoxicity?

Özdemir, Zeynep Canan; Turhan, Ali Haydar; Eren, Makbule; Bör, Özcan

doi:10.5045/br.2017.52.1.69

Cited by 6 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ALT, AST and ALP mainly exist in various tissues, such as the liver [ 25 ]. Upon liver injury, those biomarkers are released into the blood, resulting in an increase in ALT, AST and ALP levels in serum [ 26 ]. TG can accumulate in hepatocytes and result in the development of fatty liver in the early stage of alcoholic liver injury [ 27 ].…”

Section: Discussionmentioning

confidence: 99%

Bifidobacterium lactis TY-S01 protects against alcoholic liver injury in mice by regulating intestinal barrier function and gut microbiota

Shu,

Wang,

Zhao

et al. 2023

Heliyon

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Bifidobacterium lactis TY-S01 protects against alcoholic liver injury in mice by regulating intestinal barrier function and gut microbiota

Shu,

Wang,

Zhao

et al. 2023

Heliyon

View full text Add to dashboard Cite

“…Single-case observations and small case series reported that treatment with L-carnitine can result in rapid amelioration of asparaginase-induced hyperbilirubinemia. [59][60][61][62] Although this approach was successful in an animal model with pegasparaginaseinduced hepatoxicity, 63 larger studies are needed to confirm and better define this effect before L-carnitine treatment can be routinely recommended.…”

Section: Case 2: Pegasparaginase-induced Hepatotoxicitymentioning

confidence: 99%

How I Treat the Toxicities of Pegasparaginase in Adults with Acute Lymphoblastic Leukemia

Aldoss

Douer

2020

Blood

View full text Add to dashboard Cite

Administering asparaginase has always been problematic in adults since most general oncologists who treat adults are not familiar with its usage and toxicity. The toxicity profile of the drug is unique and not observed with any other chemotherapy agent. Furthermore, asparaginase is almost exclusively used in acute lymphoblastic leukemia (ALL) which is a very rare cancer in adults. Currently, the long acting pegylated form (pegasparaginase) is the only E. coli-derived asparaginase available in the US. The utilization of pediatric regimens is likely to lead to more adult patients receiving multiple doses of pegasparaginase. However, oncologists who treat adults may still be reluctant to use pegasparaginase or may unnecessarily discontinue its administration because of certain adverse effects. As a result, the clinical benefit of multiple doses of pegasparaginase will be missed. Despite the fact that pegasparaginase is associated with unique toxicities, the majority are non-fatal, manageable and reversible. Here, we describe real life cases of adults with ALL who were treated with pediatric-inspired regimens incorporating pegasparaginase to illustrate the management of several pegasparaginase-associated adverse effects and guide if and how to continue the drug.

show abstract

Asparaginase: How to Better Manage Toxicities in Adults

et al. 2022

View full text Add to dashboard Cite

Is N-acetylcysteine infusion an effective treatment option in L-asparaginase associated hepatotoxicity?

Cited by 6 publications

References 12 publications

Bifidobacterium lactis TY-S01 protects against alcoholic liver injury in mice by regulating intestinal barrier function and gut microbiota

Bifidobacterium lactis TY-S01 protects against alcoholic liver injury in mice by regulating intestinal barrier function and gut microbiota

How I Treat the Toxicities of Pegasparaginase in Adults with Acute Lymphoblastic Leukemia

Asparaginase: How to Better Manage Toxicities in Adults

Contact Info

Product

Resources

About